LeConte Wealth Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.34M Buy
1,162
+118
+11% +$139K 0.72% 34
2026
Q2
$1.25M Buy
1,044
+210
+25% +$215K 0.68% 32
2026
Q1
$767K Buy
834
+41
+5% +$41.6K 0.5% 38
2025
Q4
$852K Sell
793
-71
-8% -$67.9K 0.56% 30
2025
Q3
$659K Buy
864
+291
+51% +$217K 0.44% 34
2025
Q2
$447K Buy
573
+143
+33% +$111K 0.3% 44
2025
Q1
$355K Buy
+430
New +$358K 0.23% 36

Other funds holding LLY

LeConte Wealth Management's LLY Position: Q3 2026 in Review

LeConte Wealth Management increased its Eli Lilly (LLY) stake by 11% in Q3 2026, buying an estimated $139K and bringing the position to 1,162 shares worth $1.34M. The position accounts for 0.72% of the portfolio, ranked #34.

LeConte Wealth Management first reported a position in LLY in Q1 2025 and has held it in 7 quarters since. 1,633 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • LeConte Wealth Management held 1,162 shares of Eli Lilly worth $1.34M as of Q3 2026.
  • LeConte Wealth Management bought 118 Eli Lilly shares in Q3 2026, an estimated $139K.
  • Eli Lilly made up 0.72% of LeConte Wealth Management's portfolio in Q3 2026, its #34 holding.
  • LeConte Wealth Management first reported a position in Eli Lilly in Q1 2025 and has held it in 7 quarters since.
  • 1,633 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on LeConte Wealth Management's 13F filing for Q3 2026, filed 20 Oct 2026.